Department of Psychiatry, Shayang County People's Hospital, 448200 Jingmen, Hubei, China.
Actas Esp Psiquiatr. 2024 Apr;52(2):130-137. doi: 10.62641/aep.v52i2.1555.
To explore the impact of transcranial magnetic stimulation on emotion regulation and quality of life in patients with bipolar disorder (BD) and to evaluate the effectiveness of the mental stress analyzer.
Patients with BD admitted to our hospital from August 2022 to August 2023 were retrospectively selected. For the present study, 60 patients who received drug therapy served as the control group, and the other 60 patients who received repeated transcranial stimulation on this basis served as the observation group. The heart rate variability (HRV) of the two groups of patients was detected by a mental stress analyzer/HRV analysis system. Hamilton Depression Rating Scale (HAMD), Self-Rating Anxiety Scale (SAS), and Self-Rating Depression Scale (SDS) were used to evaluate the mental state of the two groups of patients. The quality of life of the two groups was assessed using the Comprehensive Quality of Life Questionnaire 74 (GQOLI-74). Clinical effectiveness global rating scale-illness severity (CGI-SI) was used to evaluate the clinical symptoms of the two groups of patients, and the incidence of adverse reactions was calculated.
In comparison to the control group, the high-frequency power (HF) of the patients demonstrated an elevation in the observation group, and the low-frequency power (LF) and LF/HF were significantly reduced (p < 0.05). The standard deviation of NN intervals (SDNN), standard deviation of all five-minute NN intervals (SDANN), root mean square of successive differences (rMSSD), and percent RR intervals with a difference in duration higher than 50 ms (PNN50) of patients in the observation group showed a notable increase compared to the control group (p < 0.05). Compared with the control group, the HAMD, SAS, and SDS scores of the patients in the observation group demonstrated a substantial decline relative to the control group (p < 0.05). In contrast to the control group, there was a significant increase in the overall clinical effectiveness rate among patients in the observation group, and the incidence of adverse reactions was significantly reduced (p < 0.05).
Repetitive transcranial magnetic stimulation (rTMS) has significant clinical effects in treating BD and can effectively improve patients' anxiety, suppress emotions, and regulate patients' emotions. At the same time, rTMS has high safety and little impact on the balance of patients' autonomic nervous function, reduces the incidence of adverse reactions, accelerates the patient's recovery process, and is suitable for clinical promotion.
探讨重复经颅磁刺激对双相障碍（BD）患者情绪调节和生活质量的影响，并评估精神应激分析仪的效果。
选取 2022 年 8 月至 2023 年 8 月我院收治的 BD 患者，回顾性选择 60 例接受药物治疗的患者作为对照组，另选取在此基础上接受重复经颅刺激的 60 例患者作为观察组。采用精神应激分析仪/心率变异性分析系统检测两组患者的心率变异性（HRV）。采用汉密尔顿抑郁量表（HAMD）、焦虑自评量表（SAS）和抑郁自评量表（SDS）评估两组患者的精神状态。采用生活质量综合评定问卷 74 版（GQOLI-74）评估两组患者的生活质量。采用临床疗效总体评定量表-病情严重度（CGI-SI）评估两组患者的临床症状，并计算不良反应发生率。
与对照组比较，观察组患者高频功率（HF）升高，低频功率（LF）及 LF/HF 降低（p<0.05）。观察组患者的 NN 间期标准差（SDNN）、全部 5 分钟 NN 间期标准差（SDANN）、相邻 NN 间期差值均方根（rMSSD）和差值>50 ms 的 NN 间期个数占总 NN 间期个数的百分比（PNN50）高于对照组（p<0.05）。与对照组比较，观察组患者的 HAMD、SAS 和 SDS 评分降低（p<0.05）。与对照组比较，观察组患者的总临床有效率升高，不良反应发生率降低（p<0.05）。
重复经颅磁刺激（rTMS）治疗 BD 有显著的临床效果，能有效改善患者的焦虑情绪，抑制负性情绪，调节患者的情绪。同时 rTMS 安全性高，对患者自主神经功能平衡影响小，降低不良反应发生率，加快患者康复进程，适合临床推广。
